Oura's Counsel Health Bet Feels Like a Valuation Hail Mary

In the world of health tech, there is a fine line between a strategic pivot and a desperate scramble for legitimacy. Oura's recent announcement that it is acquiring Counsel Health for $625 million looks suspiciously like the latter.

On the surface, the logic presented by Oura CEO Tom Hale is classic ecosystem expansion. As Hale noted in a press release, the integration allows members to move from understanding their physiology to taking action—ranging from prescriptions and lab results to chronic care and referrals. By bringing Counsel Health, an AI-native primary care startup, fully into the fold, Oura is attempting to transform from a hardware company that sells smart rings into a comprehensive healthcare provider.

But the timing is the real story here. As TechCrunch first reported, this acquisition comes just weeks after Oura indefinitely postponed an IPO that could have raised up to $2.2 billion, citing "uncertainty in the IPO market." When the public markets refuse to validate your valuation, you are forced to invent a new narrative to keep investors happy. In Oura's case, that narrative is "AI-native primary care."

This pivot feels less like a natural evolution and more like a reaction to two mounting pressures. First, Oura is no longer the sole titan of the smart ring market; TechCrunch notes that rivals such as Ultrahuman and RingConn are emerging to challenge its dominance. When your hardware moat shrinks, you have to find a new way to lock in users.

Second, there is the staggering $11 billion valuation Oura reached following a $900 million funding round in October 2025. While Oura's growth numbers are impressive—TechCrunch reports fiscal year 2026 revenue of approximately $1.75 billion (a 92% year-over-year increase) and quarterly revenue of $533 million—hardware margins rarely sustain an $11 billion valuation in a cooling market. By acquiring Counsel Health, Oura isn't just buying a chat-based medical experience; it's buying a new category of revenue to justify its price tag.

Counsel Health, which raised a $25 million Series A led by GV and Andreessen Horowitz (a16z) and had total estimated funding of $36 million according to PitchBook, offers a seductive promise: AI-driven care with licensed physicians in the loop. Counsel CEO Muthu Alagappan, who will join Oura as chief clinical AI officer, argues that Oura's biometric data provides clinicians with objective context for more informed care.

However, the leap from tracking sleep and activity to managing acute and chronic care is a massive operational chasm. Oura is betting that it can scale Counsel's model to enterprise partners and a broader membership base before the market realizes that a smart ring is not a substitute for a primary care infrastructure.

Ultimately, the $625 million price tag for Counsel Health isn't just an investment in AI; it is an investment in a narrative. Oura needs the world to believe it is a healthcare company, not a jewelry company, because the public markets have already signaled that the latter isn't worth $11 billion.